Thursday, 5 March 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 05 March 2026
News

Fresh PBAC agenda drops

Posted 5 March 2026 PM

Eli Lilly’s blockbuster Mounjaro is among a raft of latecomers to land on the PBAC’s March agenda, just days before the reimbursement committee’s first big meeting of the year kicks off.

Version six of the PBAC’s March meeting agenda includes five additions and two withdrawals – a change to listing for Novartis’ Scemblix in adults with newly diagnosed chronic myeloid leukaemia plus a new safety system for Sanofi’s Clexane.

To see the whole article, please login

Popular

Pharma faces biggest ever payout
New Must-Have skills in pharma
New Country boss hits goal, Day 1
Back for another tilt at subsidy
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (10)

Clinical & Medical, R&D (3)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home